YERVOY

This brand name is authorized in United States. It is also authorized in Australia, Austria, Brazil, Canada, Croatia, Cyprus, Estonia, Finland, France, Hong Kong SAR China, Ireland, Israel, Italy, Japan, Lithuania, Netherlands, New Zealand, Poland, Romania, Singapore, South Africa, Spain, Turkey, UK.

Active ingredients

The drug YERVOY contains one active pharmaceutical ingredient (API):

1	Ipilimumab UNII 6T8C155666 - IPILIMUMAB
	Ipilimumab is a CTLA-4 immune checkpoint inhibitor that blocks T-cell inhibitory signals induced by the CTLA-4 pathway, increasing the number of reactive T-effector cells which mobilize to mount a direct T-cell immune attack against tumour cells. CTLA-4 blockade can also reduce T-regulatory cell function, which may contribute to an anti-tumour immune response.
	Read more about Ipilimumab

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
YERVOY Concentrate for solution for infusion	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01FX04	Ipilimumab	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FX Other monoclonal antibodies
Discover more medicines within L01FX04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	11628B, 11644W, 12304N, 12308T, 12322M, 12324P, 12583G, 12601F, 2638W, 2641B
BR	Câmara de Regulação do Mercado de Medicamentos	505112120019302, 505112120019402
CA	Health Products and Food Branch	02379384
EE	Ravimiamet	1536926, 1536937
ES	Centro de información online de medicamentos de la AEMPS	11698001, 11698001IP, 11698002
FI	Lääkealan turvallisuus- ja kehittämiskeskus	065544, 482727
FR	Base de données publique des médicaments	66532840
GB	Medicines & Healthcare Products Regulatory Agency	193816, 193828, 369087, 377767
HK	Department of Health Drug Office	63494, 63495
IL	מִשְׂרַד הַבְּרִיאוּת	6931, 6932
IT	Agenzia del Farmaco	041275013, 041275025
JP	医薬品医療機器総合機構	4291430A1026, 4291430A2022
LT	Valstybinė vaistų kontrolės tarnyba	1061650, 1061651
NL	Z-Index G-Standaard, PRK	101052, 101060
NZ	Medicines and Medical Devices Safety Authority	15165, 15352
PL	Rejestru Produktów Leczniczych	100249251
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W65565001, W65565002
SG	Health Sciences Authority	14598P
TR	İlaç ve Tıbbi Cihaz Kurumu	8699726764109, 8699726764505
US	FDA, National Drug Code	0003-2327, 0003-2328
ZA	Health Products Regulatory Authority	47/30.1/0522